Article

Delaying Start of Cancer Treatment Reduces Chance of Survival

Time to treatment initiation of cancer treatment increased between 2004 and 2013 from 21 days to 29 days, respectively.

Prolonging time to treatment initiation (TTI) among patients with newly diagnosed cancer is associated with a significant increase in mortality, a recent Cleveland Clinic study found.

Receiving a cancer diagnosis is already mentally taxing on a patient, and waiting to start therapy only adds to the stress. Furthermore, this delay could negatively affect outcomes.

For the study, investigators used prospective data from the National Cancer Database to examine the number of days between diagnosis and first treatment for patients with newly diagnosed early-stage solid-tumor cancer from 2004 to 2013.

The study population consisted of 3,672,561 patients with breast, prostate, colorectal, non-small cell lung (NSCLC), renal, and pancreatic cancers.

The median TTI increased from 21 days in 2004 to 29 days in 2013. Determinants of delays included care at academic centers and changes in treatment facilities.

Prolonged TTI was associated with worsened overall survival (OS) among patients with stage I and II breast, lung, renal, and pancreas cancers, as well as stage II colorectal cancers. Mortality risk increased from 1.2% to 3.2% per week of delay.

Delaying TTI longer than 6 weeks was associated with substantially worsened OS. For example, the 5-year survival for stage I NSCLC was 56% for TTI of less than or equal to 6 weeks compared with 43% for TTI greater than 6 weeks. Similarly, stage I pancreas cancer was 38% compared with 29%, respectively.

“In addition to its impact on outcomes, delayed TTI can cause unnecessary stress and anxiety for patients,” said senior author Dr Brian Bolwell. “Coordinating care is challenging, particularly in academic cancer centers, but once you take the time to identify all the hurdles, and address each of them, progress in TTI is attainable.”

Two years ago, Cleveland Clinic cancer programs made it their priority to reduce TTI for cancer patients, according to a press release. Initially, TTI was similar to other major cancer centers, but has since decreased 17.5% overall. Its breast, lung, and colorectal cancer programs have seen the greatest reduction.

The Cleveland Clinic hopes to eventually reduce TTI to less than 20 days, according to the release.

“Physicians need to commit to multidisciplinary are and create integrated practice units that focus on patients,” said first author Dr Alok Khorana. “TTI needs to be measures and emphasized, and we must understand what is significant to each individual patient and not assume we already know.”

The authors concluded that “Simplifying access and navigation of complex health systems is essential to diminish this apparently iatrogenic impact on outcomes.”

The findings were presented at the 2017 ASCO annual meeting in Chicago.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards